COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry.
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2014
At a glance
- Drugs Vicriviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions
- Acronyms COVER
- Sponsors Merck & Co; Schering-Plough
- 31 Aug 2018 Biomarkers information updated
- 02 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2008 Planned end date changed from 1 Sep 2012 to 1 Sep 2015 as reported by ClinicalTrials.gov.